Citius Pharmaceuticals, Inc. (CTXR) Financial Statements (2026 and earlier)

Company Profile

Business Address 11 COMMERCE DRIVE
CRANFORD, NJ 07016
State of Incorp. NV
Fiscal Year End September 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
MRQ
9/30/2024
9/30/2023
9/30/2022
9/30/2021
9/30/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,1003,25226,48141,71270,07313,860
Cash and cash equivalent1,1003,25226,48141,71270,07313,860
Inventory, net of allowances, customer advances and progress billings14,3818,269    
Inventory14,3818,269    
Prepaid expense2,8462,7007,8902,8532,741122
Total current assets:18,32714,22134,37044,56472,81413,982
Noncurrent Assets
Operating lease, right-of-use asset191246454646823986
Property, plant and equipment   1472
Intangible assets, net (including goodwill)   9,3479,3479,3479,347
Goodwill   9,3479,3479,3479,347
Other noncurrent assets102,185102,185    
Other undisclosed noncurrent assets   59,43859,43859,43819,457
Total noncurrent assets:102,376102,43169,24169,43569,61529,792
TOTAL ASSETS:120,703116,652103,611113,999142,42943,774
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,6064,9443,4044,3333,8053,765
Interest and dividends payable 90
Employee-related liabilities1,7621,9061,655
Accounts payable7,3644,9272,9271,1651,2771,856
Accrued liabilities6,242174761,405622164
Debt     173
Other undisclosed current liabilities31,20030,8712,375197177159
Total current liabilities:44,80635,8155,7794,5303,9824,097
Noncurrent Liabilities
Long-term debt and lease obligation    4816781,020
Long-term debt, excluding current maturities      165
Liabilities, other than long-term debt6,9786,7356,4015,5624,9864,986
Deferred income tax liabilities6,9786,7146,1385,5624,9864,986
Operating lease, liability 21263481678855
Total noncurrent liabilities:6,9786,7356,4016,0435,6646,006
Total liabilities:51,78442,55012,18010,5739,64610,103
Equity
Equity, attributable to parent65,40870,07790,831102,826132,18233,671
Common stock8715914614656
Additional paid in capital276,539271,440252,904232,368228,084104,209
Accumulated deficit(211,138)(201,370)(162,231)(129,688)(96,048)(70,594)
Equity, attributable to noncontrolling interest3,5114,024600600600 
Total equity:68,91974,10291,431103,426132,78333,671
TOTAL LIABILITIES AND EQUITY:120,703116,652103,611113,999142,42943,774

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
TTM
9/30/2024
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Revenues    9090110
Other income     60110
Gross profit:    9090110
Operating expenses(42,694)(41,996)(36,732)(33,316)(23,532)(17,711)
Other undisclosed operating loss    (90)(90)(110)
Operating loss:(42,694)(41,996)(36,732)(33,316)(23,532)(17,711)
Nonoperating income2,9153,1464,765251477163
Investment income, nonoperating5277581,17925126268
Other nonoperating income   3,586   
Interest and debt expense2,3882,388  322(16)
Loss from continuing operations before equity method investments, income taxes:(37,392)(36,462)(31,967)(33,065)(22,732)(17,564)
Other undisclosed income (loss) from continuing operations before income taxes(2,388)(2,388)   16
Loss from continuing operations before income taxes:(39,780)(38,850)(31,967)(33,065)(22,732)(17,548)
Income tax expense(696)(576)(576)(576)(1) 
Loss from continuing operations:(40,476)(39,426)(32,543)(33,641)(22,733)(17,548)
Loss before gain (loss) on sale of properties:(33,641)(22,733)(17,548)
Other undisclosed net loss     (321) 
Net loss:(40,476)(39,426)(32,543)(33,641)(23,054)(17,548)
Net income attributable to noncontrolling interest513287    
Other undisclosed net income (loss) attributable to parent287     
Net loss attributable to parent:(39,676)(39,139)(32,543)(33,641)(23,054)(17,548)
Preferred stock dividends and other adjustments     (1,451) 
Other undisclosed net loss available to common stockholders, basic(1,047)(1,047)(1,151)   
Net loss available to common stockholders, diluted:(40,723)(40,186)(33,694)(33,641)(24,505)(17,548)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
TTM
9/30/2024
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Net loss:(40,476)(39,426)(32,543)(33,641)(23,054)(17,548)
Comprehensive loss:(40,476)(39,426)(32,543)(33,641)(23,054)(17,548)
Comprehensive income, net of tax, attributable to noncontrolling interest513287    
Other undisclosed comprehensive income, net of tax, attributable to parent287     
Comprehensive loss, net of tax, attributable to parent:(39,676)(39,139)(32,543)(33,641)(23,054)(17,548)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: